newsfilter
← Latest News
GlobeNewswire·

Adamis Pharmaceuticals' Clinical Study Assessing Tempol for the Treatment of COVID-19 Surpasses Enrollment Expectations

SAN DIEGO, Feb. 28, 2022 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ:ADMP) today announced that due to the acceleration of patient enrollment in the double-blind placebo controlled Phase 2/3 trial for Tempol for the treatment of COV